MCAD activation by empagliflozin promotes fatty acid oxidation and reduces lipid deposition in NASH - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35900373/
Medium chain acyl-CoA dehydrogenase (MCAD) is one of the significant enzymes involved in β-oxidation of mitochondrial fatty acids. MCAD deficiency affects the β-oxidation of fatty acid and leads to lipid deposition in multiple organs, but little is known about its importance in nonalcoholic steatohe ...
Conclusion/Relevance: Empagliflozin could upregulate MCAD expression by activating AMPK/FOXA2 signaling pathway, reduce lipid deposition and improve NASH in vivo and in vitro. This research demonstrated that MCAD is a key player of hepatic lipid deposition and it's targeting partially corrects NASH. MCAD thus may be a potential therapeutic target for the treatment of NASH.